BACKGROUND: A better definition of biomarkers and biological processes related to local recurrence and disease progression is highly warranted for ductal breast carcinoma in situ (DCIS). Stromal-epithelial interactions are likely of major importance for the biological, clinical, and pathological distinctions between high- and low-risk DCIS cases. METHODS: Stromal platelet derived growth factor receptor (PDGFR) was immunohistochemically assessed in two DCIS patient cohorts (n = 458 and n = 80). Cox proportional hazards models were used to calculate the hazard ratios of recurrence. The molecular mechanisms regulating stromal PDGFR expression were investigated in experimental in vitro co-culture systems of DCIS cells and fibroblasts and analyzed using immunoblot and quantitative real-time PCR. Knock-out of JAG1 in DCIS cells and NOTCH2 in fibroblasts was obtained through CRISPR/Cas9. Experimental data were validated by mammary fat pad injection of DCIS and DCIS-JAG1 knock-out cells (10 mice per group). All statistical tests were two-sided. RESULTS: PDGFRα(low)/PDGFRβ(high) fibroblasts were associated with increased risk for recurrence in DCIS (univariate hazard ratio = 1.59, 95% confidence interval [CI] = 1.02 to 2.46; P = .04 Wald test; multivariable hazard ratio = 1.78, 95% CI = 1.07 to 2.97; P = .03). Tissue culture and mouse model studies indicated that this fibroblast phenotype is induced by DCIS cells in a cell contact-dependent manner. Epithelial Jagged1 and fibroblast Notch2 were identified through loss-of-function studies as key juxtacrine signaling components driving the formation of the poor prognosis-associated fibroblast phenotype. CONCLUSIONS: A PDGFRα(low)/PDGFRβ(high) fibroblast subset was identified as a marker for high-risk DCIS. The Jagged-1/Notch2/PDGFR stroma-epithelial pathway was described as a novel signaling mechanism regulating this poor prognosis-associated fibroblast subset. In general terms, the study highlights epithelial-stromal crosstalk in DCIS and contributes to ongoing efforts to define clinically relevant fibroblast subsets and their etiology.
BACKGROUND: A better definition of biomarkers and biological processes related to local recurrence and disease progression is highly warranted for ductal breast carcinoma in situ (DCIS). Stromal-epithelial interactions are likely of major importance for the biological, clinical, and pathological distinctions between high- and low-risk DCIS cases. METHODS: Stromal platelet derived growth factor receptor (PDGFR) was immunohistochemically assessed in two DCIS patient cohorts (n = 458 and n = 80). Cox proportional hazards models were used to calculate the hazard ratios of recurrence. The molecular mechanisms regulating stromal PDGFR expression were investigated in experimental in vitro co-culture systems of DCIS cells and fibroblasts and analyzed using immunoblot and quantitative real-time PCR. Knock-out of JAG1 in DCIS cells and NOTCH2 in fibroblasts was obtained through CRISPR/Cas9. Experimental data were validated by mammary fat pad injection of DCIS and DCIS-JAG1 knock-out cells (10 mice per group). All statistical tests were two-sided. RESULTS:PDGFRα(low)/PDGFRβ(high) fibroblasts were associated with increased risk for recurrence in DCIS (univariate hazard ratio = 1.59, 95% confidence interval [CI] = 1.02 to 2.46; P = .04 Wald test; multivariable hazard ratio = 1.78, 95% CI = 1.07 to 2.97; P = .03). Tissue culture and mouse model studies indicated that this fibroblast phenotype is induced by DCIS cells in a cell contact-dependent manner. Epithelial Jagged1 and fibroblast Notch2 were identified through loss-of-function studies as key juxtacrine signaling components driving the formation of the poor prognosis-associated fibroblast phenotype. CONCLUSIONS: A PDGFRα(low)/PDGFRβ(high) fibroblast subset was identified as a marker for high-risk DCIS. The Jagged-1/Notch2/PDGFR stroma-epithelial pathway was described as a novel signaling mechanism regulating this poor prognosis-associated fibroblast subset. In general terms, the study highlights epithelial-stromal crosstalk in DCIS and contributes to ongoing efforts to define clinically relevant fibroblast subsets and their etiology.
Authors: Min Hu; Jun Yao; Danielle K Carroll; Stanislawa Weremowicz; Haiyan Chen; Daniel Carrasco; Andrea Richardson; Shelia Violette; Tatiana Nikolskaya; Yuri Nikolsky; Erica L Bauerlein; William C Hahn; Rebecca S Gelman; Craig Allred; Mina J Bissell; Stuart Schnitt; Kornelia Polyak Journal: Cancer Cell Date: 2008-05 Impact factor: 31.743
Authors: Min Hu; Guillermo Peluffo; Haiyan Chen; Rebecca Gelman; Stuart Schnitt; Kornelia Polyak Journal: Proc Natl Acad Sci U S A Date: 2009-02-13 Impact factor: 11.205
Authors: Shaobo Jin; Emil M Hansson; Saara Tikka; Fredrik Lanner; Cecilia Sahlgren; Filip Farnebo; Marc Baumann; Hannu Kalimo; Urban Lendahl Journal: Circ Res Date: 2008-05-15 Impact factor: 17.367
Authors: Kristian Pietras; Kristofer Rubin; Tobias Sjöblom; Elisabeth Buchdunger; Mats Sjöquist; Carl-Henrik Heldin; Arne Ostman Journal: Cancer Res Date: 2002-10-01 Impact factor: 12.701
Authors: Xiao-Jun Ma; Sonika Dahiya; Elizabeth Richardson; Mark Erlander; Dennis C Sgroi Journal: Breast Cancer Res Date: 2009-02-02 Impact factor: 6.466
Authors: Samarpan Majumder; Judy S Crabtree; Todd E Golde; Lisa M Minter; Barbara A Osborne; Lucio Miele Journal: Nat Rev Drug Discov Date: 2020-12-08 Impact factor: 84.694
Authors: Erik Sahai; Igor Astsaturov; Edna Cukierman; David G DeNardo; Mikala Egeblad; Ronald M Evans; Douglas Fearon; Florian R Greten; Sunil R Hingorani; Tony Hunter; Richard O Hynes; Rakesh K Jain; Tobias Janowitz; Claus Jorgensen; Alec C Kimmelman; Mikhail G Kolonin; Robert G Maki; R Scott Powers; Ellen Puré; Daniel C Ramirez; Ruth Scherz-Shouval; Mara H Sherman; Sheila Stewart; Thea D Tlsty; David A Tuveson; Fiona M Watt; Valerie Weaver; Ashani T Weeraratna; Zena Werb Journal: Nat Rev Cancer Date: 2020-01-24 Impact factor: 60.716